Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.
Explore and learn more about Conference Series: World’s leading Event Organizer
A substance derived from a mould or bacterium, or produced synthetically, that destroys (bactericidal) or inhibits the growth (bacteriostatic) of other microorganisms and is thus used to treat infections. Some substances have a narrow spectrum of activity whereas others act against a wide range of both gram-positive and gram-negative organisms, is destructivemicrobe substance.
OMICS International through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community. OMICS International hosted 306 open access articles Open Access articles, Scientific conference Proceedings, 1 national symposiums and on Key word antibiotics sepsis in Global Events page. Global Events of Conference series make the perfect platform for global networking as it brings together renowned speakers and scientists across the globe to a most exciting and memorable scientific event filled with much enlightening interactive sessions, world class exhibitions of OMICS International Conferences.
Importance and scope:
Numerous pathogens that have become resistant to commonly used antibiotics have been described in various contexts, including drug-resistant methycillin-resistant Staphylococcus aureus (MRSA), Streptococcus pneumoneae, and Mycobacterium tuberculosis. Antibiotics-2015 is the premier event that brings together a unique and International mix of experts, researchers and decision makers from both academia and industry across the globe to exchange their knowledge, experience and research innovations. There is a renewed interest in the antibiotic sector, which is evident from the most recent patents and investments. Bacterial vaccines and new antibiotic classes are gaining a tremendous amount of attention with several product candidates in clinical development. This conference focuses exclusively on antibiotics, bacterial vaccines, and other emerging antibacterial
New technologies and the outsourcing of antibiotics to lower-cost countries will slow the recent annual increases in expenditures in the U.S. to a 3.3% compound annual growth rate (CAGR) over the forecast period. Clinical trial spending in 2010 is an estimated $25 billion and is expected to reach $28.5 billion by 2014. The report provides an overview of clinical development phases, the regulatory issues involved, and the factors influencing clinical trial costs. An overview is provided of new technologies that will be affecting the clinical trial process in the near future.
This page will be updated regularly.
This page was last updated on 09th Sep, 2015
1-702-508-5200 Ext:8031, 8041
1-702-508-5200 Ext:8045, 8047
Immunology & Microbiology Conferences
Nursing and Healthcare Conferences
Clinical and Biochemistry Conferences
1-702-508-5200 Ext:8031, 8037
Material Science Conferences
Genetics & Mol Biology Conferences
Media Partners | Advertising